MesenchymAl stromal cells for Traumatic bRain Injury (MATRIx): a study protocol for a multicenter, double-blind, randomised, placebo-controlled phase II trial

BACKGROUND: Traumatic brain injury (TBI) is a significant cause of death and disability, with no effective neuroprotective drugs currently available for its treatment. Mesenchymal stromal cell (MSC)-based therapy shows promise as MSCs release various soluble factors that can enhance the injury micro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zanier, Elisa R., Pischiutta, Francesca, Rulli, Eliana, Vargiolu, Alessia, Elli, Francesca, Gritti, Paolo, Gaipa, Giuseppe, Belotti, Daniela, Basso, Gianpaolo, Zoerle, Tommaso, Stocchetti, Nino, Citerio, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Methodologies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449745/
https://www.ncbi.nlm.nih.gov/pubmed/37620640
http://dx.doi.org/10.1186/s40635-023-00535-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449745/
https://www.ncbi.nlm.nih.gov/pubmed/37620640
http://dx.doi.org/10.1186/s40635-023-00535-1

Ejemplares similares